Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial

Published:2019-06-25 Issue:8 Volume:46 Page:686-694
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Ohtsuki Mamitaro¹,Fujita Hideki²,Watanabe Mitsunori³,Suzaki Keiko³,Flack Mary⁴,Huang Xin⁵,Kitamura Susumu⁶^ORCID,Valdes Joaquin⁵,Igarashi Atsuyuki⁷

Affiliation:

1. Jichi Medical University Shimotsuke Japan

2. Nihon UniversityTokyo Japan

3. Nippon Boehringer Ingelheim Co., LtdTokyo Japan

4. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield ConnecticutUSA

5. AbbVie Inc. North Chicago Illinois USA

6. AbbVie G.K.Tokyo Japan

7. NTT Medical Center Tokyo Tokyo Japan

Funder

AbbVie

Boehringer Ingelheim

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.14941

Reference28 articles.

1. Psoriasis: epidemiology, clinical features, and quality of life

2. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

3. Psoriasis and comorbid diseases

4. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study

5. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04

3. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data;Frontiers in Immunology;2024-02-07

4. Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database;The Journal of Dermatology;2024-01-12

5. Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis;JEADV Clinical Practice;2024-01-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3